Intercept Down on Postponement of AdCom Meet for NASH Drug
Zacks Investment Research | May 26, 2020 01:19AM ET
Intercept Pharmaceuticals, Inc. ICPT announced that the FDA has postponed the advisory committee meeting (AdCom), which was scheduled on Jun 9, 2020 regarding the company’s new drug application (NDA) for obeticholic acid (OCA) for the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH).
Per the press release, this delay will accommodate the review of additional data requested by the regulatory body, which Intercept plans to submit within the next week. The FDA will issue a new proposed AdCom date in the future.
Earlier, the FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of Jun 26, 2020 for the completion of the review of the NDA seeking approval of OCA for liver fibrosis due to NASH. The company now expects this date to get extended as well.
Shares of Intercept have plunged 35% so far this year against the industry’s increase of 7.9%.
We remind investors that in November 2019, Intercept announced that the FDA accepted its NDA for OCA seeking accelerated approval for the treatment of fibrosis due to NASH.
The NDA filing for OCA is supported by positive interim analysis results from the pivotal phase III REGENERATE study in patients with liver fibrosis due to NASH.
In December 2019, the marketing application for OCA was submitted to the European Medicines Agency (EMA) for treating fibrosis due to NASH.
We remind investors that OCA is already approved under the brand name Ocaliva for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy for adults intolerant to UDCA. The drug generated sales of $72.7 million in the first quarter of 2020, reflecting a surge of 39% year over year.
A chronic liver disease, NASH, is caused by excessive fat accumulation in the liver or steatosis. The ailment is anticipated to be the leading cause for liver transplantation by 2020. Hence, a potential approval of OCA for NASH will significantly boost Intercept’s prospects in the days ahead.
We note that Intercept’s rival Genfit GILD candidate also failed in a late-stage study involving patients afflicted with compensated cirrhosis (F4) due to NASH.
Zacks Rank & Key Pick
Intercept currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Akcea Therapeutics (NASDAQ:AKCA), Inc. .
Get The News You Want
Akcea Therapeutics’ loss per share estimates have narrowed 33.8% for 2020 and 24.8% for 2021 over the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft (NASDAQ:MSFT) in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.